In diabetes and cardiometabolic care, the money, outcomes, and reimbursement all come from retention, not signup. Patients living with a lifelong condition disengage as soon as the product starts feeling like a chore, and each patient you lose takes their lifetime value with them. We create the retention engine – lifecycle messaging, engagement design, and win-back – that keeps patients using the product long enough to improve and pay off.
The Challenge
Your economics count on lifetime value you do not retain patients long enough to realize
Cardiometabolic business models are built on patients staying for years, but if most churn within months the lifetime value in your model is fiction. The gap between assumed and actual retention quietly breaks unit economics and every forecast built on them. Acquisition spend that looked efficient becomes a loss when the patient leaves before generating margin. Fixing retention is not a nice-to-have – it is the difference between a working model and a leaking one.
Patients disengage as soon as condition management starts to feel like a second job
Managing diabetes or cardiovascular risk is exhausting, and a product that adds friction, nags, or asks for constant effort gets abandoned even when it works. The drop-off is rarely dramatic – patients just quietly stop opening the app. In this category disengagement is also a clinical failure, because a patient who leaves stops getting the outcome. Retention marketing has to reduce the burden and reinforce the payoff, not pile on more tasks.
Your lifecycle messaging relies on generic blasts that overlook where each patient really is
A patient newly diagnosed, a patient plateauing, and a patient about to churn need completely different messages, but most companies send everyone the same newsletter. Generic messaging in a clinical journey feels tone-deaf and accelerates the disengagement it was meant to prevent. Cardiometabolic patients move through predictable phases, and messaging that meets them where they are is what sustains engagement. Blasting everyone the same thing wastes the channel and erodes trust.
Without an early-warning system, you only see churn once the patient has already left
By the time a patient formally cancels or stops logging data, they have usually been disengaging for weeks. Without leading indicators of churn risk, every intervention is a win-back attempt after the relationship is already lost. In cardiometabolic care the signals are there – declining logins, missed readings, dropped streaks – but nobody is watching them or acting. Retention requires catching the drift early, while a light touch can still bring the patient back.
How We Can Help
We begin by uncovering where and why patients actually leave. We examine your cohort retention curves, pinpoint the specific moments when patients disengage – the first plateau, the post-onboarding decline, the silent fade – and investigate the reasons. In cardiometabolic care, these inflection points are predictable, and you cannot solve churn you have not identified, so this diagnostic precedes every campaign.
Using that diagnosis, we map the patient lifecycle into meaningful phases and create messaging for each one. A newly diagnosed patient needs reassurance and early wins, a plateauing patient needs fresh motivation and a reason to continue, and an at-risk patient needs a light re-engagement touch. Every phase receives distinct messaging focused on lowering burden and reinforcing the payoff, replacing generic blasts that treat all patients alike.
Next, we create the early-warning system. We instrument the leading signs of disengagement – declining logins, missed readings, dropped adherence – and implement automated interventions that trigger while the patient can still be recovered. Identifying drift early, when a light touch is effective, is much cheaper and more successful than attempting a win-back after cancellation.
For execution, we partner with your product and lifecycle teams to make retention a designed-in feature, rather than simply a messaging layer. This means reducing the friction that causes disengagement, recognizing progress in ways that feel earned, and aligning in-product nudges with lifecycle messaging so patients experience one cohesive relationship instead of disconnected pings.
For measurement, we monitor cohort retention, engagement depth, and the retained-and-reimbursed lifetime value the business truly depends on. We assess whether interventions shift the curve for their target cohorts, and eliminate those that do not. If retention work does not bend the cohort curve, it is not working.
What sets us apart is that we manage retention as embedded operators working across product, lifecycle, and data – not as an email vendor distributing campaigns. In cardiometabolic care, retention is where the business realizes its full value, and changing it requires an operator working inside the product and the data, which is precisely where we operate.
What we deliver
- Cohort churn diagnosis – the specific moments and reasons patients disengage, mapped to the retention curve
- Lifecycle phase model with distinct messaging for newly diagnosed, plateauing, and at-risk patients built to reduce burden
- Early-warning system – instrumented disengagement signals with automated interventions that fire before churn
- Designed-in retention across the product – friction removal, earned progress moments, and coordinated in-product and lifecycle nudges
- Cohort retention and retained-reimbursed lifetime value tracking to steer which interventions get kept
In diabetes and cardiometabolic health, acquisition earns the recognition while retention generates the money. A patient living with a lifelong condition does not churn dramatically – they quietly fade weeks before canceling, and the entire challenge is detecting that drift while a light touch can still bring them back.
Our Methodology
We deliver retention marketing through a 90-day sprint. The opening 30 days focus on churn diagnosis: we evaluate cohort retention curves, identify when and why patients disengage, and instrument the leading indicators of drift. Days 30 to 60 focus on building: we develop the lifecycle phase model and phase-specific messaging, establish the early-warning system with automated interventions, and align in-product nudges with lifecycle messaging. Days 60 to 90 are for testing and tuning: we run interventions for at-risk cohorts, determine whether they bend the retention curve, and retain only those that do.
What distinguishes this from an email or lifecycle agency is that we operate across product, lifecycle, and data instead of merely sending campaigns. In cardiometabolic care, retention is a designed-in quality of the product experience, not a messaging veneer, and improving it takes an operator inside the funnel and the data. We measure the work against cohort retention and reimbursed lifetime value – the metrics the business actually depends on – rather than open rates.
Our Working Process
The initial 30 days are dedicated to diagnosis. We examine your cohort retention curves, identify the exact moments of disengagement, and instrument the early-warning signals. You will receive a clear, and sometimes uncomfortable, view of precisely where and why patients leave – the foundation for every intervention that follows.
Days 30 to 60 focus on the build. We create the lifecycle phase model, develop messaging for each phase, and launch the automated early-warning interventions. We collaborate closely with your product and lifecycle teams because retention depends as much on product friction as messaging, and both must move in tandem. From your team, we require access to product, engagement, and cohort data.
Days 60 to 90 cover testing and tuning. We deploy interventions to at-risk cohorts, evaluate whether they bend the retention curve, and remove what fails. Most engagements last three to six months, and many extend into an ongoing retention function because shifting a retention curve requires continuous effort, not a one-time solution.
Our cadence includes a weekly working session with your product and lifecycle leads, along with async cohort updates. We remain embedded in the product and data instead of sending campaigns externally, allowing retention to become a designed-in property rather than a patch.
- Cohort retention curve improvement
- Engagement depth and adherence
- Retained and reimbursed lifetime value
- Reduced churn at known disengagement points
If your diabetes & cardiometabolic health company needs retention marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does a retention marketing engagement cost for diabetes and cardiometabolic health companies?
We structure retention as a fixed monthly fee for a three-to-six-month sprint, with the range determined by the depth of data work and how much of the retention solution involves product versus messaging. Companies with well-instrumented, clean cohort data require a lighter build than companies where measurement must be established first.
How soon will we see results from a retention marketing engagement?
You will receive a clear churn diagnosis during the first 30 days, with initial interventions live by approximately day 60. Since retention is measured through cohorts over time, reading the curve reliably takes weeks, so we first monitor leading indicators such as re-engagement rates.
How does the retention marketing team work with our existing staff?
We embed within your product, lifecycle, and data teams instead of operating as a standalone email vendor. We require access to product, engagement, and cohort data, plus collaboration with product and engineering to eliminate the friction driving churn.
How is Winston Francois different from a conventional lifecycle or email agency?
A conventional agency delivers campaigns and reports on open rates. We operate across product, lifecycle, and data because retention in cardiometabolic care is a designed-in property rather than a messaging veneer, and product friction is typically the biggest driver of churn. We create an early-warning system that identifies disengagement before cancellation and measure the work against cohort retention and reimbursed lifetime value. That scope is fundamentally different from simply sending better emails.
How is ROI measured for a retention marketing engagement?
We track the cohort retention curve, depth of engagement and adherence, and retained-and-reimbursed lifetime value. We evaluate cohorts before and after interventions to make the improvement tangible and attributable. Since retention compounds against acquisition spend, even a modest improvement to the curve usually covers the engagement several times over. Open and click rates are diagnostic measures at most, never the scorecard.
What kind of diabetes and cardiometabolic health company is best suited to this service?
This service is designed for companies with roughly 5M to 100M in ARR that acquire patients reasonably effectively but lose them sooner than their economics anticipate. It works best when there is sufficient cohort data to diagnose churn and a product team prepared to address friction, rather than only send more messages. If you are pre-product-market-fit and have too few cohorts to analyze, retention work is premature. The first step with us is a strategy call and a review of your cohort retention curves.
